ロード中...
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2020-03-01
|
| シリーズ: | International Journal of Molecular Sciences |
| 主題: | |
| オンライン・アクセス: | https://www.mdpi.com/1422-0067/21/7/2275 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|